In an arthritis animal model with inducements of anti-type II collagen antibody and lipopolysaccharide (123), injection of special anti-integrin-α9 (55A2C) antibody clearly reduced the number of arthrogenic cytokines and chemokines and ameliorated ongoing arthritis, demonstrating the therapeutic potential of the anti-α9 antibody for RA (117). Here, IGKV1D-22 is linked to rheumatoid arthritis.